ASOs represent a groundbreaking therapeutic approach, targeting specific messenger RNA to impede protein production associated with various diseases, including cardiometabolic, central nervous system, oncological, and rare disorders. However, conventional antisense therapy often necessitates frequent dosing or large doses, posing significant challenges for patients.

The collaboration between Celanese's VitalDose® Drug Delivery Platform and Secarna’s ASO Drug Discovery and Development Platform aims to develop ASO-eluting implants. These implants hold the potential to reduce dosing frequency, minimize off-target immune responses, and enhance targeting, ultimately improving patient outcomes across diverse indications. Celanese's VitalDose® platform boasts reliable, controlled-release performance and a track record of approved parenteral drug products in the US and Europe, offering stable ASO release over extended periods.

Cyonna Holmes, Global Business Strategy Leader for Ophthalmology and RNA at Celanese, expressed enthusiasm about the collaboration's potential impact. "Collaborating with Secarna allows us to develop an innovative implant that has the potential to significantly change the way disease-modifying ASO therapies are administered," Holmes remarked. "Our team is eager to leverage our unique Drug Delivery Platform and expertise to address the increasing demand for patient-centric ASO solutions alongside Secarna."

Secarna Pharmaceuticals brings its proprietary ASO Drug Development and Discovery Platform to the collaboration, facilitating the discovery of novel therapies for challenging therapeutic targets. With a focus on cardiometabolic, immune-oncology, fibrotic/inflammatory diseases, and the central nervous system, Secarna has validated its platform through several high-value and innovative programs.

Konstantin Petropoulos, Chief Business Officer of Secarna Pharmaceuticals, underscored the shared vision of both companies. "We are excited to partner with Celanese to combine our industry-leading ASO platform with their VitalDose® drug delivery technology," Petropoulos stated. "Together, we envision enhancing the delivery of targeted ASO therapies, ultimately providing highly specific, potent, safe, and convenient therapeutic options for patients in need."

Research efforts will be conducted independently at Celanese's Development & Feasibility Lab, housed within a dedicated pharmaceutical facility, showcasing the commitment to advancing scientific innovation for improved patient care.